Current and potential improvements in the treatment of asthma from increased understanding of airway pathophysiology
The mainstay of chronic asthma management consists of using pharmacological agents that induce bronchodilatation, such as short-acting β-adrenergic receptor agonists (bronchodilators or relievers), and that control the chronic inflammatory process, such as corticosteroids (anti-inflammatory or contr...
Main Author: | Kian Fan Chung |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2002-01-01
|
Series: | Allergology International |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1323893015313289 |
Similar Items
-
Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review
by: Moilanen Eeva, et al.
Published: (2004-10-01) -
The role of new asthma treatments
by: K.F. Chung
Published: (1998-01-01) -
Severe asthma: anti-IgE or anti-IL-5?
by: Evgenia Papathanassiou, et al.
Published: (2016-11-01) -
Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy
by: Jesús Miguel García-Menaya, et al.
Published: (2019-05-01) -
A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences
by: Emma Kotisalmi, et al.
Published: (2020-05-01)